Why the study?
To explore the long-term prognostic value of stromal cell derived factor-1 (SDF-1) in acute coronary syndrome.
Does elevated plasma SDF-1 predict long-term mortality and major adverse cardiovascular and cerebrovascular events in patients with acute coronary syndrome?
Does elevated plasma SDF-1 predict long-term mortality and major adverse cardiovascular and cerebrovascular events in patients with acute coronary syndrome?
Elevated plasma SDF-1 levels independently predict long-term all-cause mortality and MACCE in patients with acute coronary syndrome, improving risk stratification beyond traditional factors.
Elevated SDF-1 may refine ACS prognosis beyond traditional factors; leaves open whether it warrants targeted interventions or changes practice.
Aim: To explore long-term prognostic value of SDF-1 in acute coronary syndrome (ACS). Materials & methods: We included 254 patients with ACS. Plasma SDF-1 was measured and patients were classified into tertiles of SDF-1. Results: Multivariate analysis showed third tertile of SDF-1 as an independent predictor of all-cause death (HR: 2.5; 95% CI: 1.2–5.2; p = 0.011) and the composite of major adverse cardiovascular and cerebrovascular events (HR: 1.8; 95% CI: 1.1–3.1; p = 0.031). SDF-1 added to a clinical model can improve all-cause death prediction (net reclassification improvement 0.362; 95% CI: 0.423–0.681; p = 0.027). Conclusion: SDF-1 is an independent predictor of all-cause mortality and major adverse cardiovascular and cerebrovascular events in long-term follow-up of patients with ACS and adds prognostic information beyond traditional cardiovascular risks factors.
No takes yet. Share an insight, caveat, or question.
Peiró et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: